Literature DB >> 439542

Blood levels following intravenous and endotracheal epinephrine administration.

J R Roberts, M I Greenberg, M A Knaub, Z V Kendrick, S I Baskin.   

Abstract

The blood levels of epinephrine and its metabolites which were obtained when the drug was given by both the intravenous (IV) and endotracheal (ET) routes were compared. Anesthetized dogs were subjected to radioactive epinephrine in doses of 0.005, 0.03, 0.06, and 0.09 mg/kg administered both intravenously and endotracheally. Blood levels were obtained at 0.25, 0.75, 1.5, 3, 5, 10 and 30 minutes following injection and analyzed by thin layer chromatography. The maximum measured concentration following IV injection was observed at 15 seconds. Epinephrine was rapidly metabolized with 20% of the original concentration detected at 5 minutes following IV injection. When the drug was given by the ET route, the maximum measured concentration was similarly observed at 15 seconds. Following ET installation, initial blood concentrations are sustained over a much longer period of time and 80% of the initial concentration was detected at 5 minutes. Maximum concentrations are approximately one-tenth of those achieved with an equal IV dosage. It is concluded that endotracheally and intravenously administered epinephrine rapidly reach maximum blood levels although there are differences in kinetics between the two routes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 439542     DOI: 10.1016/s0361-1124(79)80036-2

Source DB:  PubMed          Journal:  JACEP        ISSN: 0361-1124


  10 in total

1.  The potential of the nasal mucosa route for emergency drug administration via a high-pressure needleless injection system.

Authors:  Tomio Yamada
Journal:  Anesth Prog       Date:  2004

2.  Singapore Neonatal Resuscitation Guidelines 2016.

Authors:  Cheo Lian Yeo; Agnihotri Biswas; Teong Tai Kenny Ee; Amutha Chinnadurai; Vijayendra Ranjan Baral; Alvin Shang Ming Chang; Imelda Lustestica Ereno; Kah Ying Selina Ho; Woei Bing Poon; Varsha Atul Shah; Bin Huey Quek
Journal:  Singapore Med J       Date:  2017-07       Impact factor: 1.858

3.  Effects of chest compressions on cardiovascular and cerebral hemodynamics in asphyxiated near-term lambs.

Authors:  Kristina S Sobotka; Graeme R Polglase; Georg M Schmölzer; Peter G Davis; Claus Klingenberg; Stuart B Hooper
Journal:  Pediatr Res       Date:  2015-06-18       Impact factor: 3.756

Review 4.  Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

Authors:  P Pentel; N Benowitz
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

5.  Intratracheal administration of fentanyl: pharmacokinetics and local tissue effects.

Authors:  J E Irazuzta; U Ahmed; A Gancayco; S T Ahmed; J Zhang; K J Anand
Journal:  Intensive Care Med       Date:  1996-02       Impact factor: 17.440

Review 6.  Pharmacokinetics of cardiovascular drugs in children. Inotropes and vasopressors.

Authors:  C Steinberg; D A Notterman
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

7.  [Endobronchial administration of adrenaline in cardiopulmonary resuscitation: pharmacokinetic and dynamic studies in the dog].

Authors:  J Schüttler; U Hörnchen; H Stoeckel; N Hahn
Journal:  Langenbecks Arch Chir       Date:  1987

Review 8.  Drug therapy of cardiopulmonary resuscitation in children.

Authors:  A Zaritsky
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

Review 9.  Epinephrine Use during Newborn Resuscitation.

Authors:  Vishal S Kapadia; Myra H Wyckoff
Journal:  Front Pediatr       Date:  2017-05-01       Impact factor: 3.418

10.  Prophylactic epinephrine for the prevention of transbronchial lung biopsy-related bleeding in lung transplant recipients (PROPHET) study: a protocol for a multicentre randomised, double-blind, placebo-controlled trial.

Authors:  Or Kalchiem-Dekel; Aldo Iacono; Edward M Pickering; Ashutosh Sachdeva; Nirav G Shah; Mark Sperry; Bich-Chieu Tran; Robert M Reed
Journal:  BMJ Open       Date:  2019-03-23       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.